Department of Pharmaceuticals recommends export of 2000 MT in respect of Paracetamol API

The National Pharmaceutical Pricing Authority (NPPA) has allowed six major manufacturers of paracetamol active pharmaceutical ingredients (APIs) to export 2000 metric tonnes of paracetamol API. The recommendations has been issued by the Ministry of Home and Affairs.

The manufacturers mentioned below are allowed to export Paracetamol API, due to surplus availability:

Farmson Pharmaceutical -456 MT
Meghmani LLP- 209 MT
Sri Krishna Pharmaceuticals – 474 MT
Granules India- 655 MT
Bharat Chemicals- 91 MT
Para Products- 115 MT

“This is a progressive step initiated by the government by allowing the large manufacturers of paracetamol to begin the export. Since the Ministry of External Affairs is monitoring the activities of paracetamol and hydroxychloroquine (HCQ) in a licensed category and their demand position would be continuously monitored by them based on the stock position, companies would be allowed to fulfil the export commitments. The permission to export paracetamol raw materials for six large manufacturers is an encouraging step by the government. It also indicates that there will be smooth functioning of pharma exports. We look forward to permissions for other merchant exporters as well in the coming days.” Mahesh Doshi, President, Indian Drugs Manufacturers Association (IDMA) said.

B R Sikri, Chairman, Federation of Pharma Entrepreneurs (FOPE) said, “FOPE appreciates the move of the government of increasing the quantity of export of paracetamol APIs. The earlier quantity was almost 50 per cent of the current allocation, which is now 2000 metric tonnes. It shows how seriously the government is monitoring production, stock, materials in the pipeline as well as the demand-supply scenario. This is what is needed. This efficient way of working by the government will bring more such positive decisions in days to come so that neither our own people suffer for want of API or finished dosages nor the world markets which look towards India.”

  • Related Posts

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid